fashion -WSS

fashion

author：knowledge 2025-09-30 14:08:23 - browse：867

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Massive project maps cells in human brain in unprecedented detail

focus

WSS

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Akero's treatment for NASH falls short in cirrhosis study

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Risky weight loss products often used by teens globally, per study

Heart disease and mental health: A look at cardiac psychology

How I ended up pumping milk in a bathroom stall at JPM 2024

leisure time

fashion

focus

Tori Bowie and the unacceptable rates of Black maternal death

How I ended up pumping milk in a bathroom stall at JPM 2024

Medical leaders decry Supreme Court decision on affirmative action

STAT Readout: Today's biotech news includes Sana and Amylyx

BioMarin wins approval for gene therapy to treat hemophilia A

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Hepatitis C has a cure — but many Americans still lack access to it

A fraught question for the kids of Alzheimer’s: Is it coming for us?

What does generative AI mean for health care? We asked experts

Takeaways from AdvaMed, the largest medical devices conference

knowledge

Wellcome Trust names Røttingen as its new CEO

The nurse manager staffing crisis is hurting patients

Risky weight loss products often used by teens globally, per study

Caregivers of transplant patients call for more support, training

Female surgeons have lower rates of long

Wellcome Trust names Røttingen as its new CEO

explore

focus

entertainment

focus